PepsiCo's CEO, Ramon Laguarta, stated that the company has not been significantly affected by weight loss or diabetes drugs, but they are monitoring their potential impact. The popularity of semaglutide drugs in the US has increased, benefiting the drug manufacturer Novo Nordisk. PepsiCo and other food companies are offering smaller sizes and healthier options in anticipation of potential changes in consumer preferences. PepsiCo's portfolio strategy includes reducing fat, sugar, and salt and selling products in smaller packages. The company has seen success with reduced sizes and price hikes, leading to higher revenue. PepsiCo has raised its full-year forecast and its shares have increased. Sales for Gatorade, Bubly, and sodas have risen, and Pepsi plans to relaunch the Baja Blast soda.